KRAS and non-small cell lung carcinoma: After an extensive study on KRAS, only recently, in 2021, two promising inhibitors against mutated KRAS (KRASG12C) were clinically approved by the Food and Drug Administration (FDA) of the USA and the European Medicine Agency to treat advanced NSCLC patients [124,125].